Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin. 1982

G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor

One hundred one volunteers with no exposure to rabies were given human diploid cell vaccine (HDCV) for rabies with or without 20 international units of human rabies immune globulin (HRIG)/kg of body weight to evaluate schedules for therapy with HDCV and HRIG after exposure. All of the volunteers who received three or more doses of HDCV alone or four or more doses of HDCV with HRIG developed high titers of neutralizing antibodies by day 35, which persisted for at least 60 days. By day 7, of the 61 volunteers given HRIG and HDCV, 53% had neutralizing antibodies by a mouse neutralization test and 67% had neutralizing antibodies by a rapid fluorescent focus inhibition test. Similar antibody levels were found in volunteers given HRIG alone, a finding which suggests that low or undetectable early titers after administration of HDCV and HRIG were due to inadequate HRIG dosage rather than any interaction between the passive antibody (HRIG) and the vaccine antigen. These results suggest that trials with 30 or 40 international units of HRIG/kg in combination with HDCV are warranted.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820 Rabies virus The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates. Rabies viruses
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
November 1987, MMWR. Morbidity and mortality weekly report,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
September 1979, American journal of epidemiology,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
October 1991, The American journal of medicine,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
July 1978, Journal of biological standardization,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
January 1988, JAMA,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
March 1974, Applied microbiology,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
May 1984, Lancet (London, England),
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
November 1982, JAMA,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
January 1978, Developments in biological standardization,
G J Mertz, and K E Nelson, and V Vithayasai, and S Makornkawkeyoon, and E I Rosanoff, and H Tint, and T J Wiktor
March 1981, American journal of epidemiology,
Copied contents to your clipboard!